Product Information

LOPINAVIR-RITONAVR 200-50 MG TB is a generic product labeled by Camber Pharmaceuticals Inc., priced at $4.4434 per EA under NDC 31722055612. Its NADAC has been published 123 times since Apr 17, 2024.

FDA first approved this application on Jun 4, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

LOPINAVIR-RITONAVR 200-50 MG TB

Lopinavir and ritonavir
$4.4434per EA

Strength

200; 50 mg/1; mg/1

NDC

31722055612

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

LOPINAVIR; RITONAVIR

Approval Type

Generic (ANDA)

FDA Application

ANDA091677

FDA Approved

6/4/2021

TE Code

AB

On Market Since

6/7/2021

Pharmacological Classes

Breast Cancer Resistance Protein Inhibitors
Cytochrome P450 1A2 Inducers
Cytochrome P450 2B6 Inducers
Cytochrome P450 2C19 Inducers
Cytochrome P450 2C9 Inducers
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A Inducers
Cytochrome P450 3A Inhibitor
Cytochrome P450 3A Inhibitors
Cytochrome P450 3A Inhibitors
Cytochrome P450 3A4 Inhibitors
HIV Protease Inhibitors
HIV Protease Inhibitors
Organic Anion Transporting Polypeptide 1B1 Inhibitors
P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors
Protease Inhibitor
Protease Inhibitor
UDP Glucuronosyltransferases Inducers

Price Statistics

The NADAC for LOPINAVIR-RITONAVR 200-50 MG TB has been published 123 times since Apr 17, 2024, and over the history we have for it it has declined 8.5%. The table below summarizes its recorded NADAC range and movement.

Current price$4.4434 per EA
All-time high$5.3737 (Dec 11, 2024)
All-time low$4.1706 (Jun 19, 2024)
52-week high$5.2427
52-week low$4.3788
Median price$4.5520
Average price$4.6184
Largest weekly change+15.8% (Nov 20, 2024)
Weeks tracked123
Tracking sinceApr 17, 2024

Price History

1W

+0.5%

1M

+0.5%

3M

+1.5%

6M

-10.0%

1Y

-5.3%

3Y

N/A

5Y

N/A

All

-8.5%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Lopinavir and ritonavir market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of LOPINAVIR-RITONAVR 200-50 MG TB?

The current National Average Drug Acquisition Cost (NADAC) for LOPINAVIR-RITONAVR 200-50 MG TB, manufactured by Camber Pharmaceuticals Inc., is $4.4434 per EA (NDC 31722055612), effective Aug 19, 2026.

How has the price of LOPINAVIR-RITONAVR 200-50 MG TB changed over time?

Over the history we have for it, the NADAC for LOPINAVIR-RITONAVR 200-50 MG TB has declined 8.5%. It has been tracked across 123 weekly CMS publications since Apr 17, 2024.

What are the highest and lowest recorded NADAC prices for LOPINAVIR-RITONAVR 200-50 MG TB?

Since Apr 17, 2024, the NADAC for LOPINAVIR-RITONAVR 200-50 MG TB has ranged from a low of $4.1706 (Jun 19, 2024) to a high of $5.3737 (Dec 11, 2024), with a median of $4.5520 per EA.

Are there cheaper alternatives to LOPINAVIR-RITONAVR 200-50 MG TB?

No other NADAC-published product currently shares the active ingredient and strength of LOPINAVIR-RITONAVR 200-50 MG TB in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures LOPINAVIR-RITONAVR 200-50 MG TB?

LOPINAVIR-RITONAVR 200-50 MG TB (NDC 31722055612) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.